Willis Towers Watson plc 8.3
Source: RNS
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
|
Name of person dealing (Note 1) |
J.P. Morgan Securities LLC |
|
Company dealt in |
Willis Towers Watson plc |
|
Class of relevant security to which the dealings being disclosed relate (Note 2) |
US$0.000304635 ordinary shares |
|
Date of dealing |
01 July 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long |
Short |
||||
|
|
Number |
|
(%) |
Number |
|
(%) |
|
(1) Relevant securities |
1,812,501 1.41 |
1,713,508 1.33 |
||||
|
(2) Derivatives (other than options) |
1,581,833 1.23 |
1,664,590 1.29 |
||||
|
(3) Options and agreements to purchase/sell
|
7,800 0.01 |
24,600 0.02 |
||||
|
Total |
3,402,134 2.65 |
3,402,698 2.64 |
||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
|
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
|
Sale (Borrow Return)
Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase
Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale |
65,700
10 200 15 200 6 700 3 100 200 200 100 200 200 300 297 31 200 1 4 6,097 38 100 38
100 1 15 1 3 100 1 1 1 6 6 700 3 25 3 1 22 2 18 100 4 23 3 2 13 100 1 100 6 100 100 6 100 1 3 3 4 300 161 262 200 100 1 2 31 101 7,240 401 22 1 1 1 38 1 100 1 38 |
N/A
233.1650 USD 233.1200 USD 232.4607 USD 231.9400 USD 231.6850 USD 231.6643 USD 231.5950 USD 231.5126 USD 231.4700 USD 231.4100 USD 231.3600 USD 231.3400 USD 231.3100 USD 231.1759 USD 231.1202 USD 231.0974 USD 231.0600 USD 231.0300 USD 231.0200 USD 231.0000 USD 230.7600 USD 230.6400 USD 230.0200 USD
233.1200 USD 232.7900 USD 232.4607 USD 232.4400 USD 231.9900 USD 231.9400 USD 231.8700 USD 231.8100 USD 231.7400 USD 231.6950 USD 231.6850 USD 231.6643 USD 231.6150 USD 231.6048 USD 231.5950 USD 231.5800 USD 231.5536 USD 231.5000 USD 231.4894 USD 231.4700 USD 231.4675 USD 231.4552 USD 231.4433 USD 231.4400 USD 231.4180 USD 231.4100 USD 231.3800 USD 231.3400 USD 231.3150 USD 231.3100 USD 231.3000 USD 231.2750 USD 231.2500 USD 231.2300 USD 231.2200 USD 231.1933 USD 231.1825 USD 231.1759 USD 231.1553 USD 231.1447 USD 231.1100 USD 231.0600 USD 231.0450 USD 231.0200 USD 231.0175 USD 231.0100 USD 231.0000 USD 230.9820 USD 230.9636 USD 230.9600 USD 230.8500 USD 230.8300 USD 230.7600 USD 230.7100 USD 230.6700 USD 230.5650 USD 230.0200 USD |
(b) Derivatives transactions (other than options transactions)
|
Product name, e.g. CFD |
Nature of transaction (Note 6) |
Number of relevant securities (Note 7) |
Price per unit (USD) (Note 5) |
|
Equity Swap |
Decrease Short
Increase Short |
3
300 |
231.6150 USD
231.1759 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price (USD) |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) (USD) |
|
Put Option |
Purchasing |
24,000 |
220.00 |
American |
20/08/2021 |
4.05 |
(ii) Exercising
|
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) Yes
|
Date of disclosure |
02 July 2021 |
|
Contact name |
Alwyn Basch |
|
Telephone number |
0207 742 7407 |
|
If a connected EFM, name of offeree/offeror with which connected |
N/A |
|
If a connected EFM, state nature of connection (Note 10) |
N/A |
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
|
Product name, e.g. call option |
Written, or purchased |
Number of relevant securities to which the option or derivative relates |
Exercise price (Note 2) (USD) |
Type, e.g. American, European etc. |
Expiry date |
|
Call Option Put Option Put Option Put Option |
Purchased Purchased Written Written |
3,900 3,900 24,000 600 |
240.00 220.00 220.00 250.00 |
American American American American |
16/07/2021 16/07/2021 20/08/2021 16/07/2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
